Setting the stage: The silent liver epidemic employers can’t ignore
MASH (metabolic dysfunction–associated steatohepatitis) is emerging as one of the fastest-growing, most expensive and serious complications of obesity and type 2 diabetes. Yet, for many employers and health plans, it remains largely invisible.
An estimated 5% of U.S. adults — roughly 1 in 20 people — live with MASH, often without a formal diagnosis or symptoms. (*1) As rates of obesity, insulin resistance, and cardiovascular disease continue to climb, so too does the prevalence of progressive liver disease.
The issue has become even more urgent with FDA approval of Wegovy (semaglutide) for noncirrhotic MASH with moderate to advanced fibrosis. While this approval represents an important clinical milestone, it also introduces new complexity for employers and plan sponsors, particularly around patient selection, appropriate use, and long-term cost management.
Understanding MASH
GLP-1 medications (like Wegovy, Zepbound, and Ozempic) are effective tools when used responsibly and paired with behavior chMASH is a progressive inflammatory liver disease driven by metabolic dysfunction. It develops when excess fat accumulates in the liver, triggering chronic inflammation and, over time, fibrosis. Without intervention, MASH can progress to cirrhosis, liver failure, transplantation, cancer, and even death in some extreme cases.
The terminology surrounding fatty liver disease has evolved to reflect advances in scientific understanding. What was previously referred to as “non-alcoholic fatty liver disease” (NAFLD) is now more accurately described as “metabolic dysfunction-associated steatotic liver disease” (MASLD). MASH represents the more severe, inflammatory subtype within this spectrum.
This shift in language reflects a growing clinical consensus that metabolic dysfunction, not alcohol use, is the primary driver of disease for most patients. For benefits leaders, this reframing is critical. It positions liver disease squarely within the cardiometabolic continuum, rather than as a standalone issue.
The metabolic domino effect
MASH does not occur in isolation. It is the downstream result of interconnected metabolic processes that often unfold silently over years. In clinical terms, the progression typically follows a familiar pattern:
- Visceral fat accumulates and leads to insulin resistance
- Insulin resistance impairs glucose regulation
- Excess liver fat accumulates as metabolic pathways face irregularities
- Chronic inflammation develops within the liver tissue
- Fibrosis forms, increasing the progressive risks
- Fibrosis worsens and leads to complications
This sequence explains why MASH is so tightly linked to obesity, type 2 diabetes, dyslipidemia, and cardiovascular disease. It also explains why many individuals remain undiagnosed until later stages due to a lack of obvious symptoms.
While approximately 20-30% of U.S. adults are estimated to have “metabolic dysfunction-associated steatotic liver disease” (MASLD), MASH represents the higher-risk, higher-cost segment of that population.
At roughly 13 million affected individuals in the U.S. alone (*2), MASH is already a substantial burden on the healthcare system with significant downstream costs including increased hospitalizations, specialist referrals, advanced imaging and biopsies, long-term monitoring and even measures as extreme as growing demand for liver transplantation.
From a population health perspective, MASH represents a predictable but preventable complication of poorly monitored and controlled metabolic disease. And for employers, these costs can often intersect with another pressure point: rising utilization of GLP-1 therapies.
As new indications expand, unmanaged prescribing can quickly drive pharmacy and specialty spend without delivering proportional clinical value.
The new treatment landscape is changing the stakes
The FDA approval of Wegovy for noncirrhotic MASH with moderate to advanced fibrosis marks an important shift in treatment options. For the first time, GLP-1s play a formal role in managing this condition. It does, however, raise new and critical questions for employers as more members may meet eligibility criteria and more providers may feel empowered to prescribe.
Without proper guardrails, the risk of over-prescribing or misaligned use increases, and clinical nuance becomes even more important in determining who truly benefits. Recent findings from The BMJ “suggest caution in short-term use of these drugs without a more comprehensive approach to weight management,” solely based on weight gain after cessation. All in all, pharmacotherapy does not replace lifestyle intervention, and sustained improvements in liver health and obesity depend heavily on addressing the underlying metabolic drivers of disease.
Why lifestyle intervention is the frontline treatment
Employers and health plans are under pressure to act — but also to act wisely. With the rising demand for obesity care, coverage The evidence is clear: lifestyle modification is foundational to MASLD and MASH treatment. Improvements in nutrition, physical activity, and metabolic health can meaningfully reduce liver fat, inflammation, and even early fibrosis.
Studies consistently show that 7-10% sustained weight loss can lead to significant improvements in liver inflammation and disease progression, yet achieving and maintaining this level of change remains difficult for many individuals. (*3)
Although lifestyle change is clinically effective, it is rarely sustainable without coordinated, longitudinal support. In employer-sponsored populations, low disease awareness, fragmented care, and limited behavioral infrastructure often prevent members from translating evidence into durable outcomes—creating a clear need for an integrated care model.
At Vida, we have comprehensive, clinically validated care for MASH
TWe approach MASH for what it is: a high-impact cardiometabolic condition that requires integrated, longitudinal care. Our model builds on our existing cardiometabolic portfolio and brings together:
- Registered dietitians with expertise in metabolic and liver health
- Physicians and prescribers experienced in evidence-based obesity and metabolic care
- Behavioral coaches to support sustained lifestyle change
- Mental health support, integrated appropriately
Each member receives a personalized care plan grounded in clinical evidence, focusing on nutrition, weight management, physical activity, metabolic monitoring, and medications as needed. This care is integrated with GLP-1 therapy or other appropriate medications for the treatment or MASH as part of a broader metabolic strategy—not as a standalone solution.
Vida’s treatment of MASH includes:
1. Identifying the right members for MASH treatment (including semaglutide)
Effective MASH management depends on precision, not volume.
Vida uses structured clinical intake, laboratory data, and risk stratification to identify appropriate members who may benefit from pharmacotherapy. By applying clear clinical criteria and ongoing oversight, we have a process in place that supports appropriate evaluation, prescribing, and monitoring for patients who qualify for semaglutide or other MASH treatments, while preventing unnecessary utilization for those who don’t.
2. Containing costs through precision treatment
Our approach enables a carve-out-ready care model that moves beyond one-size-fits-all solutions. The goal is simple: deliver the right treatment, at the right time, with measurable outcomes. For employers, this translates into
- Improved liver-related clinical markers
- Better overall metabolic control
- Reduced disease progression
- Fewer downstream complications & avoidable costs
Looking ahead
MASH is a top strategic priority in cardiometabolic care
From a clinical perspective, MASH today looks very much like type 2 diabetes did ten years ago: widespread, frequently undiagnosed, and progressing quietly. Employers that act early can play a meaningful role in improving outcomes while containing long-term medical costs.
As GLP-1 indications expand and cardiometabolic complexity grows, proactive, evidence-based strategies will be essential, as will a partner like Vida. We are expanding to meet this need with scalable, clinically validated care designed for the realities of our health landscape.
The question for benefits leaders is no longer whether liver disease belongs in cardiometabolic care, but whether their current program is equipped to address it.
